The point-of-care glucose testing market size has grown strongly in recent years. It will grow from $5.14 billion in 2025 to $5.44 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising prevalence of diabetes, increased adoption of self-monitoring practices, availability of affordable glucose meters, expansion of outpatient diabetes care, growing awareness of glycemic control.
The point-of-care glucose testing market size is expected to see strong growth in the next few years. It will grow to $6.95 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growing adoption of connected glucose monitoring systems, rising integration with mobile health applications, increasing demand for non-invasive monitoring, expansion of remote patient monitoring programs, growing focus on personalized diabetes management. Major trends in the forecast period include increasing adoption of bluetooth-enabled glucose meters, rising use of continuous glucose monitoring devices, growing preference for home-based glucose testing, expansion of digital diabetes management platforms, enhanced focus on patient self-monitoring.
The increasing prevalence of diabetes is expected to drive the growth of the point of care glucose testing market going forward. Diabetes is a chronic metabolic condition that leads to elevated blood glucose levels and, over time, can cause serious damage to the heart, blood vessels, eyes, kidneys, and nerves. Point of care glucose testing is widely used to monitor glucose levels in hospitalized patients, enabling timely treatment decisions in response to changes in glycemia and improving overall therapeutic outcomes and diabetes management. For instance, in June 2024, according to the National Health Service (NHS England), a UK-based publicly funded healthcare system, the number of individuals identified as having pre-diabetes in England increased to 3,615,330 in 2023, representing an 18% rise from 3,065,825 in 2022. In addition, among people under the age of 40, cases increased by nearly 25%, rising from 173,166 in 2022 to 216,440 in 2023. Therefore, the growing prevalence of diabetes is contributing to the growth of the point of care glucose testing market.
Major companies operating in the point of care glucose testing market are focusing on technological advancements such as wearable continuous glucose monitoring systems with predictive analytics to support real time glucose tracking, improve glycemic control, and reduce the need for frequent manual testing. Continuous glucose monitoring systems use a small sensor placed under the skin to continuously measure interstitial glucose levels and transmit data to a mobile application, enabling proactive management through real time alerts and trend forecasting. For instance, in July 2024, Roche, a Switzerland-based diagnostics company, launched the Accu-Chek SmartGuide continuous glucose monitoring system for people with diabetes. The system delivers real time glucose readings every five minutes, incorporates AI driven trend predictions up to two hours in advance, provides overnight alerts for hypo or hyperglycemia, and integrates with a mobile app for data tracking and remote monitoring, offering greater safety and convenience compared with traditional finger prick glucose meters.
In August 2024, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired point of care technology from LumiraDx Ltd. for an undisclosed amount. Through this acquisition, Roche aims to strengthen its diagnostics portfolio by incorporating a flexible platform capable of consolidating multiple tests on a single instrument, supporting the expansion of decentralized healthcare solutions. LumiraDx Ltd. is a UK-based point of care diagnostics company that provides glucose testing solutions.
Major companies operating in the point-of-care glucose testing market are F Hoffmann-La Roche Ltd., Abbott Laboratories Inc., Siemens Healthineers, TaiDoc Technology Corporation, Nipro Corporation, Dexcom Inc., LifeScan Inc., Nova Biomedical Corporation, Ypsomed AG, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Radiometer Medical ApS, HemoCue AB, EKF Diagnostics Holdings plc, Trinity Biotech plc, Bionime Corporation, PTS Diagnostics, ForaCare Inc., Menarini Diagnostics, ACON Laboratories Inc., Senseonics Holdings Inc., Prodigy Diabetes Care LLC, Nemaura Medical Inc., Medtronic plc.
North America was the largest region in the point-of-care glucose testing market in 2025. The regions covered in the point-of-care glucose testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care glucose testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point-of-care glucose testing market by increasing costs of imported biosensors, electronic chips, testing strips, and plastic components used in meters and consumables. Healthcare providers and homecare users in North America and Europe are most affected due to reliance on imported test strips and electronic components, while Asia-Pacific faces export pricing pressure. These tariffs are contributing to higher consumable costs and affecting affordability for frequent testing. However, they are also encouraging domestic production of glucose strips, localized assembly of meters, and supply chain resilience for essential diabetes monitoring tools.
The point-of-care glucose testing market research report is one of a series of new reports that provides point-of-care glucose testing market statistics, including point-of-care glucose testing industry global market size, regional shares, competitors with a point-of-care glucose testing market share, detailed point-of-care glucose testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care glucose testing industry. This point-of-care glucose testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point of care glucose testing refers to a quality assured pathology service provided near the patient rather than within a traditional clinical laboratory setting. It enables glucose testing by healthcare professionals or individuals using small handheld devices or glucose analyzers that employ test strips to analyze whole blood. This approach shortens the time between sample collection and result availability, allowing quicker therapeutic intervention, reducing preanalytical errors, and improving overall patient care.
The primary products used in point of care glucose testing include lancets and lancing devices, test strips, and glucose meters. Lancets are small, sharp tools used to prick the skin and obtain a drop of blood, while lancing devices securely hold the lancet and operate with a simple push button mechanism. These components are used together in point of care glucose testing to facilitate easy blood sampling and measurement of blood glucose levels using glucose monitors and test strips. Testing is commonly performed at fingertip sites or alternative sites and is applied in the management of type 1 diabetes and type 2 diabetes. These products are used by various end users, including professional diagnostic centers, hospitals and clinics, home care settings, and others.
The point-of-care glucose testing market consists of revenues earned by entities by providing services such as diagnosis, monitoring, screening, and testing regimes to offer enhanced therapeutic intervention and patient care in lesser time. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care glucose testing market also includes sales of rapid assay dipsticks, glucose monitoring kits, and multifunctional benchtop devices which are used in providing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The point-of-care glucose testing market size is expected to see strong growth in the next few years. It will grow to $6.95 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growing adoption of connected glucose monitoring systems, rising integration with mobile health applications, increasing demand for non-invasive monitoring, expansion of remote patient monitoring programs, growing focus on personalized diabetes management. Major trends in the forecast period include increasing adoption of bluetooth-enabled glucose meters, rising use of continuous glucose monitoring devices, growing preference for home-based glucose testing, expansion of digital diabetes management platforms, enhanced focus on patient self-monitoring.
The increasing prevalence of diabetes is expected to drive the growth of the point of care glucose testing market going forward. Diabetes is a chronic metabolic condition that leads to elevated blood glucose levels and, over time, can cause serious damage to the heart, blood vessels, eyes, kidneys, and nerves. Point of care glucose testing is widely used to monitor glucose levels in hospitalized patients, enabling timely treatment decisions in response to changes in glycemia and improving overall therapeutic outcomes and diabetes management. For instance, in June 2024, according to the National Health Service (NHS England), a UK-based publicly funded healthcare system, the number of individuals identified as having pre-diabetes in England increased to 3,615,330 in 2023, representing an 18% rise from 3,065,825 in 2022. In addition, among people under the age of 40, cases increased by nearly 25%, rising from 173,166 in 2022 to 216,440 in 2023. Therefore, the growing prevalence of diabetes is contributing to the growth of the point of care glucose testing market.
Major companies operating in the point of care glucose testing market are focusing on technological advancements such as wearable continuous glucose monitoring systems with predictive analytics to support real time glucose tracking, improve glycemic control, and reduce the need for frequent manual testing. Continuous glucose monitoring systems use a small sensor placed under the skin to continuously measure interstitial glucose levels and transmit data to a mobile application, enabling proactive management through real time alerts and trend forecasting. For instance, in July 2024, Roche, a Switzerland-based diagnostics company, launched the Accu-Chek SmartGuide continuous glucose monitoring system for people with diabetes. The system delivers real time glucose readings every five minutes, incorporates AI driven trend predictions up to two hours in advance, provides overnight alerts for hypo or hyperglycemia, and integrates with a mobile app for data tracking and remote monitoring, offering greater safety and convenience compared with traditional finger prick glucose meters.
In August 2024, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired point of care technology from LumiraDx Ltd. for an undisclosed amount. Through this acquisition, Roche aims to strengthen its diagnostics portfolio by incorporating a flexible platform capable of consolidating multiple tests on a single instrument, supporting the expansion of decentralized healthcare solutions. LumiraDx Ltd. is a UK-based point of care diagnostics company that provides glucose testing solutions.
Major companies operating in the point-of-care glucose testing market are F Hoffmann-La Roche Ltd., Abbott Laboratories Inc., Siemens Healthineers, TaiDoc Technology Corporation, Nipro Corporation, Dexcom Inc., LifeScan Inc., Nova Biomedical Corporation, Ypsomed AG, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Radiometer Medical ApS, HemoCue AB, EKF Diagnostics Holdings plc, Trinity Biotech plc, Bionime Corporation, PTS Diagnostics, ForaCare Inc., Menarini Diagnostics, ACON Laboratories Inc., Senseonics Holdings Inc., Prodigy Diabetes Care LLC, Nemaura Medical Inc., Medtronic plc.
North America was the largest region in the point-of-care glucose testing market in 2025. The regions covered in the point-of-care glucose testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the point-of-care glucose testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the point-of-care glucose testing market by increasing costs of imported biosensors, electronic chips, testing strips, and plastic components used in meters and consumables. Healthcare providers and homecare users in North America and Europe are most affected due to reliance on imported test strips and electronic components, while Asia-Pacific faces export pricing pressure. These tariffs are contributing to higher consumable costs and affecting affordability for frequent testing. However, they are also encouraging domestic production of glucose strips, localized assembly of meters, and supply chain resilience for essential diabetes monitoring tools.
The point-of-care glucose testing market research report is one of a series of new reports that provides point-of-care glucose testing market statistics, including point-of-care glucose testing industry global market size, regional shares, competitors with a point-of-care glucose testing market share, detailed point-of-care glucose testing market segments, market trends and opportunities, and any further data you may need to thrive in the point-of-care glucose testing industry. This point-of-care glucose testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Point of care glucose testing refers to a quality assured pathology service provided near the patient rather than within a traditional clinical laboratory setting. It enables glucose testing by healthcare professionals or individuals using small handheld devices or glucose analyzers that employ test strips to analyze whole blood. This approach shortens the time between sample collection and result availability, allowing quicker therapeutic intervention, reducing preanalytical errors, and improving overall patient care.
The primary products used in point of care glucose testing include lancets and lancing devices, test strips, and glucose meters. Lancets are small, sharp tools used to prick the skin and obtain a drop of blood, while lancing devices securely hold the lancet and operate with a simple push button mechanism. These components are used together in point of care glucose testing to facilitate easy blood sampling and measurement of blood glucose levels using glucose monitors and test strips. Testing is commonly performed at fingertip sites or alternative sites and is applied in the management of type 1 diabetes and type 2 diabetes. These products are used by various end users, including professional diagnostic centers, hospitals and clinics, home care settings, and others.
The point-of-care glucose testing market consists of revenues earned by entities by providing services such as diagnosis, monitoring, screening, and testing regimes to offer enhanced therapeutic intervention and patient care in lesser time. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care glucose testing market also includes sales of rapid assay dipsticks, glucose monitoring kits, and multifunctional benchtop devices which are used in providing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Point-of-Care Glucose Testing Market Characteristics
3. Point-of-Care Glucose Testing Market Supply Chain Analysis
4. Global Point-of-Care Glucose Testing Market Trends and Strategies
5. Point-of-Care Glucose Testing Market Analysis of End Use Industries
7. Global Point-of-Care Glucose Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Point-of-Care Glucose Testing Total Addressable Market (TAM) Analysis for the Market
9. Point-of-Care Glucose Testing Market Segmentation
10. Point-of-Care Glucose Testing Market Regional and Country Analysis
11. Asia-Pacific Point-of-Care Glucose Testing Market
12. China Point-of-Care Glucose Testing Market
13. India Point-of-Care Glucose Testing Market
14. Japan Point-of-Care Glucose Testing Market
15. Australia Point-of-Care Glucose Testing Market
16. Indonesia Point-of-Care Glucose Testing Market
17. South Korea Point-of-Care Glucose Testing Market
18. Taiwan Point-of-Care Glucose Testing Market
19. South East Asia Point-of-Care Glucose Testing Market
20. Western Europe Point-of-Care Glucose Testing Market
21. UK Point-of-Care Glucose Testing Market
22. Germany Point-of-Care Glucose Testing Market
23. France Point-of-Care Glucose Testing Market
24. Italy Point-of-Care Glucose Testing Market
25. Spain Point-of-Care Glucose Testing Market
26. Eastern Europe Point-of-Care Glucose Testing Market
27. Russia Point-of-Care Glucose Testing Market
28. North America Point-of-Care Glucose Testing Market
29. USA Point-of-Care Glucose Testing Market
30. Canada Point-of-Care Glucose Testing Market
31. South America Point-of-Care Glucose Testing Market
32. Brazil Point-of-Care Glucose Testing Market
33. Middle East Point-of-Care Glucose Testing Market
34. Africa Point-of-Care Glucose Testing Market
36. Point-of-Care Glucose Testing Market Competitive Landscape and Company Profiles
37. Point-of-Care Glucose Testing Market Other Major and Innovative Companies
40. Point-of-Care Glucose Testing Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Point-of-Care Glucose Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses point-of-care glucose testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for point-of-care glucose testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point-of-care glucose testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Lancet And Lancing Devices; Strips; Meters2) By Testing Site: Fingertips; Alternate Site Testing
3) By Applications: Type-1 Diabetes; Type-2 Diabetes
4) By End-User: Professional Diagnostic Centers; Hospitals And Clinics; Home Care Settings; Other End Users
Subsegments:
1) By Lancet And Lancing Devices: Single-Use Lancets; Multi-Use Lancets; Adjustable Lancing Devices2) By Strips: Glucose Test Strips; Ketone Test Strips; Combo Strips (Glucose And Ketone)
3) By Meters: Blood Glucose Meters; Continuous Glucose Monitoring (CGM) Meters; Bluetooth-Enabled Meters
Companies Mentioned: F Hoffmann-La Roche Ltd.; Abbott Laboratories Inc.; Siemens Healthineers; TaiDoc Technology Corporation; Nipro Corporation; Dexcom Inc.; LifeScan Inc.; Nova Biomedical Corporation; Ypsomed AG; Ascensia Diabetes Care Holdings AG; Trividia Health Inc.; Radiometer Medical ApS; HemoCue AB; EKF Diagnostics Holdings plc; Trinity Biotech plc; Bionime Corporation; PTS Diagnostics; ForaCare Inc.; Menarini Diagnostics; ACON Laboratories Inc.; Senseonics Holdings Inc.; Prodigy Diabetes Care LLC; Nemaura Medical Inc.; Medtronic plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Point-of-Care Glucose Testing market report include:- F Hoffmann-La Roche Ltd.
- Abbott Laboratories Inc.
- Siemens Healthineers
- TaiDoc Technology Corporation
- Nipro Corporation
- Dexcom Inc.
- LifeScan Inc.
- Nova Biomedical Corporation
- Ypsomed AG
- Ascensia Diabetes Care Holdings AG
- Trividia Health Inc.
- Radiometer Medical ApS
- HemoCue AB
- EKF Diagnostics Holdings plc
- Trinity Biotech plc
- Bionime Corporation
- PTS Diagnostics
- ForaCare Inc.
- Menarini Diagnostics
- ACON Laboratories Inc.
- Senseonics Holdings Inc.
- Prodigy Diabetes Care LLC
- Nemaura Medical Inc.
- Medtronic plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.44 Billion |
| Forecasted Market Value ( USD | $ 6.95 Billion |
| Compound Annual Growth Rate | 6.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
